Usefulness of a nanoparticle formulation to investigate some hemodynamic parameters of a poorly soluble compound

Journal of Pharmaceutical Sciences

Volumn 100, Issue 6, 2011, Pages 2194-2202

  Sigfridsson, Kalle ^a,b   Björkman, Jan Arne ^a   Skantze, Pia ^a   Zachrisson, Helen ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Injectables; Intravenous; Nanoparticles; Pharmacokinetics; Preclinical; Stability; Ticagrelor

Indexed keywords

NANOPARTICLE; SOLVENT; TICAGRELOR;

ANIMAL EXPERIMENT; AORTA PRESSURE; ARTICLE; BLOOD FLOW; BLOOD PRESSURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; FEMORAL ARTERY FLOW; HEART OUTPUT; HEART RATE; HEMODYNAMICS; INFUSION RATE; INOTROPISM; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; RAT; ROOM TEMPERATURE; SUSPENSION;

EID: 79954472440     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22440     Document Type: Article

References (35)

1. Lipinski CA. 2002. Poor aqueous solubility-an industry wide problem in drug discovery. Am Pharm Rev 5:82-85.
2. Serajuddin ATM. 2007. Salt formation to improve drug solubility. Adv Drug Deliv Rev 59:603-616.
3. Hargrove JT, Maxson WS, Wentz AC. 1989. Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol 161:948-951.
4. Hirasawa N, Ishise S, Miyata H, Danjo K. 2003. An attempt to stabilize nilvadipine solid dispersion by the use of ternary systems. Drug Dev Ind Pharm 29:997-1004.
5. Loftsson T, Brewster ME. 1996. Pharmaceutical applications of cyclodextrins. J Pharm Sci 85:1017-1025.
6. Stella VJ, Rajewski RA. 1997. Cyclodextrins: Their future in drug formulation and delivery. Pharm Res 14:556-567.
7. Floyd AG. 1999. Top ten considerations in the development of parenteral emulsions. Pharm Sci Tech 4:134-143.
8. Lawrence MJ, Rees GD. 2000. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 45:89-121.
9. Nakano N. 2000. Places of emulsions in drug delivery. Adv Drug Deliv Rev 45:1-4.
10. Akers MJ. 2002. Excipient-drug interactions in parenteral formulations. J Pharm Sci 91:2283-2300.
11. Pifferi G, Restani P. 2003. The safety of pharmaceutical excipients. Farmaco 58:541-550.
12. Jia L, Wong J, Cerna C, Weitman S. 2002. Effect of nanonization on absorption of 301029: Ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm Res 19:1091-1096.
13. Merisko-Liversidge E, Liversidge GG, Cooper ER. 2003. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18:113-120.
14. Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U. 2006. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir 22:906-910.
15. Lindfors L, Forssen S, Skantze P, Skantze U, Zackrisson A, Olsson U. 2006. Amorphous drug nanosuspensions. 2. Experimental determination of bulk monomer concentrations. Langmuir 22:911-916.
16. Sigfridsson K, Lundqvist AJ, Strimfors M. 2009. Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development. Drug Dev Ind Pharm 35:1479-1486.
17. Müller RH, Peters K. 1998. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by size-reduction technique. Int J Pharm 160:229-237.
18. Rabinow BE. 2004. Nanosuspensions in drug delivery. Nat Rev 3:785-796.
19. Mauludin R, Müller RH, Keck CM. 2009. Kinetic solubility and dissolution velocity of rutin nanocrystals. Eur J Pharm Sci 36:502-510.
20. Liversidge GG, Conzentino P. 1995. Drug particle reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm 125:309-313.
21. Liversidge GG, Cundy K. 1995. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 125:91-97.
22. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. 2002. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 16:53-61.
23. Jacobs C, Müller RH. 2002. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 19:189-194.
24. Wong J, Brugger A, Khare A, Chaubal M, Papadopoulos P, Rabinow B, Kipp J, Ning J. 2008. Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects. Adv Drug Deliv Rev 60:939-959.
25. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. 2007. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598-1660.
26. Husted S, van Giezen JJ. 2009. Ticagrelor: The first reversibly binding oral P2Y receptor antagonist. Cardiovasc Ther 27:259-274.
27. AstraZeneca, data on file to be published.
28. US National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH publication no. 85-23, revised1985).
29. 12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thromb Res 124:565-571.
30. Folts J. 1991. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 83(6 suppl):3-14.
31. Huang LF, Tong WQ. 2004. Impact of solid state properties on developability assessment of drug candidates. Adv Drug Deliv Rev 56:321-334.
32. Müller RH, Jacobs C, Kayser O. 2001. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47:3-19.
33. Clement M, Pugh W, Parikh I. 1992. Tissue distribution and plasma clearance of a novel microcrystalline-coated flurbiprofen formulation. Pharmacologist 34:204.
34. Sigfridsson K, Forsen S, Holländer P, Skantze U, de Verdier J. 2007. A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound. Eur J Pharm Biopharm 67:540-547.
35. Björkman J-A, Kirk I, van Giezen JJ. 2007. AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischaemia or intracoronary adenosine infusion. Circulation 116(suppl):II-28.